American Academy of Allergy, Asthma, and Immunology

Sublingual Immunotherapy May Result in Desensitization and Remission for Peanut-Allergic Children

Retrieved on: 
Tuesday, October 10, 2023

MILWAUKEE, Oct. 10, 2023 /PRNewswire-PRWeb/ -- Peanut sublingual immunotherapy (SLIT) is safe for young children and results in a greater likelihood of desensitization and remission, according to new research published in The Journal of Allergy and Clinical Immunology (JACI), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points: 
  • 60% of peanut-allergic children in the test group experience desensitization to peanut protein after sublingual immunotherapy according to research from JACI, an official journal of the AAAAI.
  • Upon assessment, 60% of children in the study were found to experience desensitization to peanut protein, and 48% experienced remission three months after therapy.
  • Conducted over a 36-month period, the double-blind, placebo-controlled study assessed the effectiveness of peanut sublingual immunotherapy (SLIT) on 50 children aged 1- to 4 years old.
  • Upon assessment, 60% of children in the study were found to experience desensitization to peanut protein, and 48% experienced remission three months after therapy.

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

Retrieved on: 
Tuesday, October 3, 2023

JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.

Key Points: 
  • JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.
  • The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.
  • For repeat doses of neffy, mean maximum changes in PD responses for both blood pressure and heart rate were statistically greater than repeat doses of EpiPen.
  • In addition, the PK profile for a second dose of neffy was approximately dose-proportional, unlike EpiPen, where the second dose delivered less incremental epinephrine exposure than the first dose.

New Stock Epinephrine and Stock Inhaler Toolkits Improve Safety of Students with Anaphylaxis and Asthma

Retrieved on: 
Thursday, August 17, 2023

MILWAUKEE, Aug. 17, 2023 /PRNewswire-PRWeb/ -- New stock inhaler and stock epinephrine toolkits from The School-Based Asthma, Allergy and Anaphylaxis Committee (SA3MPRO™) of the American Academy of Allergy, Asthma & Immunology (AAAAI) empower schools to develop and implement high-quality stock epinephrine stock inhaler policies.

Key Points: 
  • New stock inhaler and stock epinephrine toolkits from the AAAAI provide critical emergency care for students with allergies and asthma.
  • MILWAUKEE, Aug. 17, 2023 /PRNewswire-PRWeb/ -- New stock inhaler and stock epinephrine toolkits from The School-Based Asthma, Allergy and Anaphylaxis Committee (SA3MPRO™) of the American Academy of Allergy, Asthma & Immunology (AAAAI) empower schools to develop and implement high-quality stock epinephrine stock inhaler policies.
  • Despite asthma and anaphylactic allergies impacting millions of children in the American school system, the development and implementation of stock inhaler and epinephrine policies remains slow-going.
  • The SA3MPRO™ stock inhaler and stock epinephrine toolkits seek to mitigate barriers and address state-level differences in policy implementation.

McGovern Allergy & Asthma Clinic Welcomes Dr. An Nguyen to Their Team of Houston Allergists!

Retrieved on: 
Thursday, August 10, 2023

HOUSTON, Aug. 10, 2023 /PRNewswire-PRWeb/ -- Dr. An Nguyen is making significant strides in Allergy and Immunology with her extensive educational background and dedication to providing comprehensive and personalized treatment to individuals of all ages. Dr. Nguyen obtained her doctorate from UT Southwestern and further specialized in Internal Medicine during her Baylor College of Medicine residency. Her relentless pursuit of knowledge led her to complete a fellowship in Allergy and Immunology at the same prestigious institution. During her fellowship, Dr. Nguyen focused on groundbreaking research, investigating the role of vitamin D in the immunomodulation of allergic disease and the impact of fungi on sinus disease and asthma. Inspired by her experience with allergies and eczema, Dr. Nguyen chose to specialize in Allergy and Immunology. She believes that her journey enables her to empathize with patients on a deeper level while providing invaluable education to empower them to manage their conditions effectively.

Key Points: 
  • Dr. An Nguyen, a highly accomplished and compassionate medical professional, joins the McGovern Allergy & Asthma Clinic team.
  • Dr. Nguyen obtained her doctorate from UT Southwestern and further specialized in Internal Medicine during her Baylor College of Medicine residency.
  • Her relentless pursuit of knowledge led her to complete a fellowship in Allergy and Immunology at the same prestigious institution.
  • Dr. Nguyen emphasizes the importance of seeking specialized care from an allergy specialist to address allergy and asthma symptoms.

Asthma Patients Undergoing Regular High-intensity Exercise May be Able to Reduce Daily Inhaled Corticosteroid Dosage

Retrieved on: 
Wednesday, May 31, 2023

MILWAUKEE, May 31, 2023 /PRNewswire-PRWeb/ -- Supervised high-intensity interval training could reduce the need for inhaled corticosteroids (ICS) in asthma patients who had not previously undergone this type of exercise, supporting exercise as a nonpharmacological component of asthma management. The finding comes from a new study published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), a journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points: 
  • Patients in the exercise group were able to reduce doses without compromising their asthma control according to research from JACI: In Practice, an official journal of the AAAAI.
  • MILWAUKEE, May 31, 2023 /PRNewswire-PRWeb/ -- Supervised high-intensity interval training could reduce the need for inhaled corticosteroids (ICS) in asthma patients who had not previously undergone this type of exercise, supporting exercise as a nonpharmacological component of asthma management.
  • The control group maintained their regular lifestyle while the exercise group underwent six months of ongoing supervised high-intensity exercise three times a week.
  • April Presnell, The American Academy of Allergy, Asthma & Immunology, (414) 272-6071, [email protected]
    SOURCE The American Academy of Allergy, Asthma & Immunology

Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, May 11, 2023

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
  • We on track to share initial proof-of-concept results which are anticipated in mid-2024,” said Jill C. Milne, Ph.D., Chief Executive Office at Astria.
  • In the fourth quarter of 2023, the company expects initial Phase 1a results from the additional cohorts in healthy subjects, as well as final results from cohorts 1 through 3.
  • She will be responsible for leading the company’s Corporate Strategy, Business Development, Investor Relations, Corporate Communications, and Patient Advocacy functions.

Women's Exposure to Domestic Violence Associated with Risk of Developing Atopic Diseases

Retrieved on: 
Friday, May 5, 2023

MILWAUKEE, May 5, 2023 /PRNewswire-PRWeb/ -- Being a woman exposed to domestic violence and abuse is positively associated with the development of atopic disease, with the association strongest for asthma development, according to research published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), a journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points: 
  • "After adjusting for possible cofounders, our results show women with a recorded exposure to domestic violence and abuse had a 52% increased risk of developing atopic diseases," said Dr Joht Singh Chandan, PhD, corresponding author of the study.
  • "We set out to deepen our understanding of the health impacts of domestic violence so evidence-based public health policies can be further developed to address not only domestic violence, but secondary effects like the development of atopic diseases," Dr. Chandan said.
  • A total of 13,852 women were identified as being exposed to domestic violence and were matched to 49,036 similar women without a reported exposure.
  • If you or someone you know is experiencing domestic violence, visit the National Domestic Violence Hotline website or contact their hotline at 1-800-799-7233 for assistance.

EBSCO Information Services Names Christina Barnes, MSN, RN, CPNP, Dynamic Health™ Section Editor in Pediatrics

Retrieved on: 
Thursday, April 6, 2023

IPSWICH, Mass., April 6, 2023 /PRNewswire-PRWeb/ -- EBSCO Information Services (EBSCO), the preeminent provider of evidence-based clinical decision support resources, has appointed Christina Barnes, MSN, RN, CPNP, High-Acuity Pediatric Section Editor for Dynamic Health™. Dynamic Health is an evidence-based resource designed to help nurses and health care professionals master skills, obtain fast answers to clinical questions and foster evidence-based practice, helping to improve patient care.

Key Points: 
  • IPSWICH, Mass., April 6, 2023 /PRNewswire-PRWeb/ -- EBSCO Information Services ( EBSCO ), the preeminent provider of evidence-based clinical decision support resources, has appointed Christina Barnes, MSN, RN, CPNP, High-Acuity Pediatric Section Editor for Dynamic Health ™.
  • Barnes is a board-certified Pediatric Nurse Practitioner with deep experience in pediatric and neonatal intensive care nursing.
  • As High-Acuity Pediatrics Section Editor, Barnes will provide editorial oversight on the NICU and PICU content within Dynamic Health.
  • Christina brings extensive pediatric experience to the team, adding a layer of oversight to help advance our content."

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today highlighted recent progress and reported fourth quarter and full year 2022 financial results.

Key Points: 
  • We believe we are well on our way to achieving this goal,” said Richard Lowenthal, president and chief executive officer of ARS Pharmaceuticals.
  • R&D Expenses: Research and development (R&D) expenses were $4.7 million for the quarter ended December 31, 2022, and $18.4 million for the year ended December 31, 2022.
  • G&A Expenses: General and administrative (G&A) expenses were $10.7 million for the quarter ended December 31, 2022, and $18.5 million for the year ended December 31, 2022.
  • Net Loss: Net loss was $14.4 million for the quarter ended December 31, 2022, and $34.7 million for the year ended December 31, 2022.

Fellowship-Trained Allergist and Immunologist Karina Rotella, MD Joins ENT and Allergy Associates, LLP Yorktown Heights, NY Office

Retrieved on: 
Wednesday, March 22, 2023

Tarrytown, New York, March 22, 2023 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), is proud to announce that fellowship-trained allergist and immunologist Karina Rotella, MD will join their Yorktown Heights office effective August 1, 2023.

Key Points: 
  • Tarrytown, New York, March 22, 2023 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), is proud to announce that fellowship-trained allergist and immunologist Karina Rotella, MD will join their Yorktown Heights office effective August 1, 2023.
  • During this transition, Dr. Peter Gontzes will cover the Yorktown Heights office to ensure a seamless care transition for patients.
  • She is a member of the American College of Allergy, Asthma & Immunology, the American Academy of Allergy, Asthma & Immunology, and the New York Allergy and Asthma Society.
  • Rotella is the perfect fit for our Yorktown Heights office,” noted Dr. Debra Reich, Senior Partner at the Yorktown Heights office of ENTA.